02.18.25 -- From JP Morgan: CDMOs Have A Change Of Heart

Clinical trials in complex therapeutic areas require more than just a solid strategy—they demand proactive and engaged operational leadership from the sponsor side. Join our expert panel to discuss how an active and knowledgeable Clin Ops lead, in collaboration with an experienced outsourcing project lead, can drive informed decision-making, enhance efficiency, and ultimately ensure trial success. Click to learn more.

Explore how two-column AAV processes can enhance yield and potency while maintaining high-quality standards in the production of gene therapy products.

mRNA therapy and vaccine manufacturing can be complex when working with multiple CMOs, making partnering with an end-to-end CMO essential to overcoming these challenges.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

Certain roles must be filled before you move into manufacturing to avoid costly delays and incur non-value-added expenses. Uncover what those roles are and get ideas on how to fill them.

Learn about the development and effective scale-up of a robust process for manufacturing adenovirus vectors and the obstacles that were encountered and successfully overcome.

This study introduces validated methods for quantifying AAV9 capsid titer and host-cell-derived impurities, offering a solution for enhancing rAAV batch release testing.

Transposase-mediated genome engineering enables the robust and stable relocation of discrete DNA segments (transposons) in the genome, providing a valuable tool for stable transgene expression.

As the field grows, understanding how to formulate RNA nanoparticles effectively is essential for advancing therapeutic innovations.

Review a demonstration of a scalable, high-yield triple-transfection rAAV platform's efficiency, enabling gene therapy production with strong performance and streamlined processes.

View the presentation and learn how efficient project management and optimized communication are cornerstones of a successful cell and gene transfer process.

See how a Design of Experiment (DoE) model was applied to address the multifactorial nature of large-scale transfection, where multiple variables collectively impact efficiency.

With the increasing demand for cell and gene therapies, CZ nested vials can help the biopharma industry overcome the challenges of scaling up manufacturing and logistics.

Achieve scalable purity with Vernal Biosciences' mRNA and LNP production, tailored for preclinical studies, dose range finding, and toxicology assessments.

With nearly three decades of viral vector expertise, we offer a scalable, efficient solution to de-risk lentivirus production.

The XS® Pichia Expression System allows you to develop scalable, robust, and reliable processes to express your biologics drugs with improved productivity.

Choose from our technology platforms or have our scientists customize a project using our patented RACE™ protocol for quality, accuracy, and fast turnaround.

Our team has decades of cell and gene therapy development experience and can help you achieve maximum return on investment.

Consider our one-stop shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications.